dazatoN, yes it is it, this kind of a meeting with FDA needs to happen before a new study can start. FDA can give advice and tell to do changes to the study plan. ATH has been planing this ph 2 for a long time, but only now after this meeting, it can start to work according to the plan.
Ann: Meeting with US FDA provides development path for ATH434, page-3
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $100.4M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.1¢ | 1.0¢ | $34.89K | 3.172M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 38 | 12240482 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 24557711 | 8 |
View Market Depth
| Last trade - 15.27pm 16/06/2025 (20 minute delay) ? |
| ATH (ASX) Chart |